Drug intelligence / Profile preview

ESG403

Development stage: Preclinical
Lead developer: Shanghai Escugen Biotechnology
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ESG403 is an investigational antibody-drug conjugate (ADC) developed by Shanghai Escugen Biotechnology for the treatment of solid tumors. The drug is designed to deliver a cytotoxic payload directly to cancer cells by targeting a specific cell-surface antigen, the identity of which is currently confidential. ESG403 is part of Escugen's oncology-focused pipeline, which leverages proprietary ADC technology to enhance the precision and efficacy of cancer therapies while minimizing systemic toxicity.

Targets

TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on ESG403.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ESG403.

Explore the full profile